Gillespie Deirdre 4
4 · LA JOLLA PHARMACEUTICAL CO · Filed May 18, 2011
Insider Transaction Report
Form 4
Gillespie Deirdre
DirectorPresident & CEO
Transactions
- Exercise/Conversion
Common Stock
2011-05-09$0.01/sh+99,166$595→ 99,166 total - Sale
Common Stock
2011-05-17$0.02/sh−99,166$1,587→ 0 total - Exercise/Conversion
Series C-1 Convertible Preferred
2011-05-09$595.00/sh−0.595$354→ 111.205 totalExercise: $0.01→ Common (99,166 underlying)
Footnotes (4)
- [F1]Shares issued on conversion of Series C-1 Convertible Preferred. The Series C-1 Convertible Preferred has a face value of $1,000 per share and was convertible into Common Stock at a ratio of 166,667 shares of Common Stock per share of Series C-1 Convertible Preferred.
- [F2]Reflects the price following a one-time adjustment on May 7, 2011 after the Company's 100 to 1 reverse split.
- [F3]Exercisable date is not applicable.
- [F4]Expiration date is not applicable.